ZA201708595B - Stuffy nose deblocking composition having antiviral activity - Google Patents

Stuffy nose deblocking composition having antiviral activity

Info

Publication number
ZA201708595B
ZA201708595B ZA2017/08595A ZA201708595A ZA201708595B ZA 201708595 B ZA201708595 B ZA 201708595B ZA 2017/08595 A ZA2017/08595 A ZA 2017/08595A ZA 201708595 A ZA201708595 A ZA 201708595A ZA 201708595 B ZA201708595 B ZA 201708595B
Authority
ZA
South Africa
Prior art keywords
antiviral activity
stuffy nose
composition
nose deblocking
deblocking composition
Prior art date
Application number
ZA2017/08595A
Other languages
English (en)
Inventor
Andreas Grassauer
Eva Prieschl-Grassauer
Angelika Bodenteich
Christiane Koller
Martina Morokutti-Kurz
Original Assignee
Marinomed Biotechnologie Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marinomed Biotechnologie Gmbh filed Critical Marinomed Biotechnologie Gmbh
Publication of ZA201708595B publication Critical patent/ZA201708595B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731Carrageenans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA2017/08595A 2015-07-14 2017-12-18 Stuffy nose deblocking composition having antiviral activity ZA201708595B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15176670 2015-07-14
PCT/EP2016/066565 WO2017009351A1 (en) 2015-07-14 2016-07-12 Stuffy nose deblocking composition having antiviral activity

Publications (1)

Publication Number Publication Date
ZA201708595B true ZA201708595B (en) 2021-06-30

Family

ID=53717900

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/08595A ZA201708595B (en) 2015-07-14 2017-12-18 Stuffy nose deblocking composition having antiviral activity

Country Status (26)

Country Link
US (1) US10660914B2 (cg-RX-API-DMAC7.html)
EP (1) EP3370692B1 (cg-RX-API-DMAC7.html)
JP (1) JP6774435B2 (cg-RX-API-DMAC7.html)
KR (1) KR102628781B1 (cg-RX-API-DMAC7.html)
CN (1) CN107847430B (cg-RX-API-DMAC7.html)
AU (1) AU2016293004B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018000592B1 (cg-RX-API-DMAC7.html)
CA (1) CA2992352C (cg-RX-API-DMAC7.html)
CL (1) CL2018000033A1 (cg-RX-API-DMAC7.html)
DK (1) DK3370692T3 (cg-RX-API-DMAC7.html)
EA (1) EA037085B1 (cg-RX-API-DMAC7.html)
ES (1) ES2949139T3 (cg-RX-API-DMAC7.html)
FI (1) FI3370692T3 (cg-RX-API-DMAC7.html)
HU (1) HUE062108T2 (cg-RX-API-DMAC7.html)
IL (1) IL256883B (cg-RX-API-DMAC7.html)
LT (1) LT3370692T (cg-RX-API-DMAC7.html)
MA (1) MA43155A (cg-RX-API-DMAC7.html)
MX (1) MX372625B (cg-RX-API-DMAC7.html)
MY (1) MY194870A (cg-RX-API-DMAC7.html)
NZ (1) NZ738597A (cg-RX-API-DMAC7.html)
PH (1) PH12018500044B1 (cg-RX-API-DMAC7.html)
PL (1) PL3370692T3 (cg-RX-API-DMAC7.html)
PT (1) PT3370692T (cg-RX-API-DMAC7.html)
SA (1) SA518390689B1 (cg-RX-API-DMAC7.html)
WO (1) WO2017009351A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201708595B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017220396B2 (en) * 2016-02-17 2022-12-15 Ent Technologies Pty Ltd Compositions and methods for the treatment of sinus disease and disorders
GB2567285A (en) * 2017-08-07 2019-04-10 Suprapharm Cc Preparation for nasal-nasopharyngeal treatment
PH12022552298A1 (en) 2020-03-12 2023-12-11 Cullis Hill Sydney David Treatment for coronavirus infection and associated cytokine toxicity
CN111437270A (zh) * 2020-04-24 2020-07-24 瑞希(重庆)生物科技有限公司 一种卡拉胶鼻用即型凝胶喷雾剂及其制备方法
US11013687B1 (en) * 2020-06-08 2021-05-25 Amcyte Pharma, Inc. Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2
WO2021253643A1 (zh) * 2020-06-18 2021-12-23 大连工业大学 硫酸化多糖在抗新型冠状病毒中的应用
CN111686125A (zh) * 2020-06-18 2020-09-22 大连工业大学 卡拉胶在抗新型冠状病毒中的应用
BR112022026026A2 (pt) * 2020-06-22 2023-03-07 Elmen Tremblay Mario Lubrificantes pessoais compreendendo lambda-carragenina
EP3939597A1 (en) * 2020-07-16 2022-01-19 Marinomed Biotech AG Antiviral pharmaceutical composition comprising a carrageenan component
US20230330013A1 (en) * 2020-08-04 2023-10-19 Cosmosoft Hydrogel comprising glycerol and a carbomer for treating the respiratory symptoms of covid-19 disease via the nasal route
FR3113237B1 (fr) 2020-08-04 2023-06-09 Biopass Produit pour le traitement de maladies virales par voie nasale
DE202020004186U1 (de) * 2020-10-05 2020-10-21 Christian Fleischhammel Antiinfektive Arzneiform zur Herstellung einer Nasenspülung gegen COVID-19
EP3991561A1 (en) * 2020-10-28 2022-05-04 Vepidan ApS Antimicrobial disinfectant gel
GB202109888D0 (en) 2021-07-08 2021-08-25 Pollinner Ltd Nasal spray
KR102720037B1 (ko) * 2021-12-21 2024-10-22 (주)메디코어 비강 세정제 조성물 및 그 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2653021A1 (fr) * 1989-10-17 1991-04-19 Merck Sharp & Dohme Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
US6080783A (en) * 1998-09-01 2000-06-27 Gum Tech International, Inc. Method and composition for delivering zinc to the nasal membrane
NZ555501A (en) * 2004-11-24 2010-01-29 Medpointe Healthcare Inc Compositions comprising azelastine and methods of use thereof
US20080241271A1 (en) * 2006-11-08 2008-10-02 Roman Stephen B Foaming anti-adhesion composition
PL2101792T3 (pl) 2006-12-05 2010-11-30 Marinomed Biotechnologie Gmbh Zastosowanie karageniny do leczenia zakażeń rinowirusem
JP4941977B2 (ja) * 2007-04-11 2012-05-30 大蔵製薬株式会社 ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物
CA2696009C (en) 2007-08-24 2016-08-02 Marinomed Biotechnologie Gmbh Antiviral composition comprising a sulfated polysaccharide
JP5634066B2 (ja) * 2007-11-06 2014-12-03 三栄源エフ・エフ・アイ株式会社 唾液分泌促進剤
FR2926218B1 (fr) 2008-01-10 2010-08-13 Galderma Res & Dev Composition comprenant un retinoide et du peroxyde de benzoyle disperse.
WO2013049538A1 (en) * 2011-09-30 2013-04-04 Mcneil-Ppc, Inc. Allergen nasal compositions

Also Published As

Publication number Publication date
JP2018523635A (ja) 2018-08-23
CA2992352C (en) 2023-06-27
EA037085B1 (ru) 2021-02-04
EP3370692A1 (en) 2018-09-12
AU2016293004B2 (en) 2021-05-06
MA43155A (fr) 2018-09-12
PH12018500044B1 (en) 2022-04-27
NZ738597A (en) 2021-12-24
IL256883A (en) 2018-03-29
FI3370692T3 (fi) 2023-06-16
CN107847430A (zh) 2018-03-27
CN107847430B (zh) 2021-02-02
LT3370692T (lt) 2023-07-10
PH12018500044A1 (en) 2018-07-23
SA518390689B1 (ar) 2021-07-17
PT3370692T (pt) 2023-07-18
PL3370692T3 (pl) 2023-08-14
EA201890196A1 (ru) 2018-06-29
MX2018000285A (es) 2018-02-19
KR20180054570A (ko) 2018-05-24
DK3370692T3 (da) 2023-06-26
MX372625B (es) 2020-05-12
HK1253038A1 (zh) 2019-06-06
JP6774435B2 (ja) 2020-10-21
KR102628781B1 (ko) 2024-01-24
US20190060358A1 (en) 2019-02-28
ES2949139T3 (es) 2023-09-25
IL256883B (en) 2021-07-29
CL2018000033A1 (es) 2018-08-10
BR112018000592B1 (pt) 2024-02-06
BR112018000592A2 (pt) 2018-09-11
US10660914B2 (en) 2020-05-26
WO2017009351A1 (en) 2017-01-19
EP3370692B1 (en) 2023-04-12
CA2992352A1 (en) 2017-01-19
AU2016293004A1 (en) 2018-01-18
MY194870A (en) 2022-12-21
HUE062108T2 (hu) 2023-09-28

Similar Documents

Publication Publication Date Title
IL256883B (en) Preparations with antiviral activity to prevent nasal congestion
PT3162232T (pt) Capacete
GB2555990B (en) Face mask assembly
GB201511641D0 (en) Helmet
GB2551920B (en) Mask system headgear
GB201508114D0 (en) Respirator tab
TWM476614U (en) Nose mask
AU366140S (en) Safety goggle
SG11201707117SA (en) Ophthalmic composition
PL3285606T3 (pl) Ochrona ciała
IL256441B (en) New p450–bm3 variants with enhanced activity
GB201703369D0 (en) Antiviral composition
PL3308662T3 (pl) Struktura maski na twarz
EP3279323A4 (en) Amadoriase having improved specific activity
IL257971A (en) Materials with combined activity
ZA201706440B (en) Gene therapy to improve vision
IL254481A0 (en) protective mask
IL257351A (en) ventilation group
GB201519631D0 (en) Sprays
GB201507328D0 (en) Helmet
GB201521405D0 (en) Teather
GB201518828D0 (en) Seven eleven
GB201522515D0 (en) Leavening agent
TWD174410S (zh) 上機箱
GB201512431D0 (en) Leavening agent